A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Assess The Efficacy And Safety Of Omecamtiv Mecarbil On Mortality And Morbidity In Subjects With Chronic Heart Failure With Reduced Ejection Fraction
Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active
This is a randomized, placebo-controlled, double-blind, parallel group, multicenter, CV outcomes study in subjects with HFrEF, including subjects with ongoing or history of HF hospitalization. The study is event-driven and will conclude when approximately 1590 CV death events have occurred. Approximately 8000 eligible subjects will be randomized in a 1:1 ratio to receive either OM or placebo.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.